Search Results
Your search for ,NOn matches 5550 pages
Showing 4201 - 4250Anti–PD-1/PD-L1 Antibodies Make Strong Showing in Gastrointestinal Cancers
Although the results may not yet be as impressive as those seen in melanoma, lung, and kidney cancers, monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) are producing responses, with some durability, in gastrointestinal cancers, according to studies presented at the 2016...
Intense Tumor Lymphocytic Infiltration Prognostic of Better Outcome in Resectable NSCLC
Intense tumor lymphocytic infiltration was associated with improved outcomes in patients with resectable non–small cell lung cancer, according to a study reported in the Journal of Clinical Oncology by Brambilla et al. Study Details The LACE-Bio (Lung Adjuvant Cisplatin Evaluation...
Dutch Study Shows Increased Risk of Second Cancer for Survivors of Hodgkin Lymphoma During Long-Term Follow-up
In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...
Younger T Cells May Improve Immunotherapy for Pediatric Cancer
Pediatric oncologists from The Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and broaden a novel personalized cell therapy to treat children with cancer. The researchers say that a patient’s outcome may be improved if clinicians select specific...
Addition of TG4010 Vaccine to First-Line Chemotherapy Appears to Improve Progression-Free Survival in Advanced NSCLC
As reported in The Lancet Oncology by Quoix et al, the addition of immunotherapy with TG4010—the modified vaccinia Ankara expressing MUC1 and interleukin 2—to first-line chemotherapy improved progression-free survival in patients with advanced non–small cell lung cancer (NSCLC) in ...
Alectinib in ALK-Positive Metastatic NSCLC After Crizotinib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, alectinib (Alecensa) was granted...
Improved Outcomes in Patients With Germ Cell Testicular Tumors in the Modern Era
Although patients with poor-risk metastatic testicular germ cell tumors continue to have less favorable outcomes, the bar has been raised by contemporary treatment. There is still room for improvement in managing metastatic testicular germ cell tumors, especially in poor-risk patients, but if...
'Doctor, We Prayed for You'
A 70-year-old female patient underwent a cardiac procedure to repair her mitral valve, and at the same time, she also underwent a coronary artery bypass grafting. She had an uneventful course for the first four postoperative days. On the sixth postoperative day, she started complaining of abdominal ...
Higher Mortality Risk in Poor or Minority Adolescents and Young Adults vs White Patients With Hodgkin Lymphoma
Despite improvements in survival for adolescents and young adults diagnosed with Hodgkin lymphoma, the gains have not been shared uniformly across this patient population. A large population-based study by Keegan et al investigating the impact of race/ethnicity, socioeconomic status, influence of...
Afatinib Shows Clinical Benefit for Non–Small Cell Lung Cancer Patients With Brain Metastases
Non–small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival and response from the EGFR tyrosine kinase inhibitor afatinib (Gilotrif) compared to standard platinum doublet chemotherapy....
Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer
Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.
Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma
James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care
Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.
Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Charles F. von Gunten, MD, PhD, Discusses Anamorelin and Olanzapine for Palliative Care
Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).
Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL
Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).
Ramaswamy Govindan, MD: Roundup of Lung Cancer Findings
Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung...
Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors
Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).
Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small cell lung cancer (Abstract PLEN04.03).
Roy S. Herbst, MD, PhD, on Results From SWOG S0819
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of...
Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagnosing these patients at an earlier stage.
Lorraine Cheryl Pelosof, MD, PhD, on Never-Smokers in NSCLC
Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with non–small cell lung cancer (Abstract ORAL 22.01).
Tony Mok, MD, and Alice Shaw, MD, PhD: Expert Perspectives on ALK Inhibition and Brigatinib
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial...
Jean-Charles Soria, MD, PhD, on Results of the KEYNOTE 001 Clinical Trial
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).
Rolf A. Stahel, MD, on Results From the BELIEF Trial
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology...
Stephen G. Chun, MD, on NSCLC: Results From NRG Oncology/RTOG 0617
Stephen G. Chun, MD, of MD Anderson Cancer Center, discusses the comparison of 3D conformal and IMRT outcomes for locally advanced non-small cell lung cancer (Abstract 2).
Brian D. Kavanagh, MD, on Improving Value and Elevating the Patient Care Experience
Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients...
W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular genetics and its impact on treatment, how to treat patients with non-clear cell histology, and the best strategy for...
Cancer Incidence in Indigenous People in Australia, New Zealand, Canada, and the United States
In a population-based study reported in The Lancet Oncology, Suzanne P. Moore, PhD, of Charles Darwin University, Northern Territory, Australia, and colleagues compared cancer incidence in indigenous people in Australia, New Zealand, Canada, and the United States with the incidence in nonindigenous ...
Stage Increase in Lung Cancer More Frequent After Open vs Closed Thoracic Surgery
An increase in the stage of non–small cell lung cancer (NSCLC) due to cancer-positive lymph node discovery was more common following open chest surgery for lung lobe removal of early-stage lung cancer compared to the closed-chest procedure known as video-assisted thoracic surgery (VATS). The...
Winning the Battle at the Front Lines: Lenalidomide Plus Rituximab— A Promising Initial Treatment for Mantle Cell Lymphoma
Mantle cell lymphoma is a pernicious, incurable disease. Front-line therapies for this disease are not currently standardized; however, novel therapies for relapsed or refractory mantle cell lymphoma can ideally be translated into beneficial treatments for newly diagnosed patients, as clearly...
Two Inherited Genetic Variants Predict Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
In a genome-wide association study reported in Journal of Clinical Oncology, Hervé Ghesquieres, MD, PhD, of Centre Léon Bérard, Lyon, France, and colleagues identified two inherited genetic variants that were associated with poorer event-free and overall survival in patients with diffuse large...
The Evolving Treatment Landscape of ALK-Positive NSCLC
Since the initial discovery of ALK rearrangement in non–small cell lung cancer (NSCLC) in 2007,1 small molecule tyrosine kinase inhibitors of ALK have transformed the course of disease for those patients with ALK-rearranged (ie, ALK-positive) NSCLC. Crizotinib (Xalkori), a multitargeted tyrosine...
Global and North American Phase II Studies Show Alectinib Is Highly Active in Crizotinib-Resistant/Refractory ALK-Rearranged NSCLC
In two phase II trials, reported in the Journal of Clinical Oncology and The Lancet Oncology, the ALK inhibitor alectinib (Alecensa), which is active against acquired crizotinib resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable...
Expert Point of View: Sagar Lonial, MD
Responding to the assertion that bortezomib (Velcade)/lenalidomide (Revlimid)/low-dose dexamethasone induction followed by continuous lenalidomide/dexamethasone is potentially a new standard of care in newly diagnosed multiple myeloma, Sagar Lonial, MD, Chief Medical Officer of Winship Cancer...
Immunotherapy for Breast Cancer: Early Lackluster Study Results yet Promise Remains
Immunotherapy is at the forefront of exciting new approaches to cancer, with excellent and long-lasting responses in metastatic melanoma and non–small cell lung cancer (NSCLC) and several immunotherapy agents now approved for those malignancies by the U.S. Food and Drug Administration (FDA). The...
Study Finds Colorectal Cancer More Likely to Affect Minorities at Younger Age
Researchers at the University of Missouri School of Medicine reported that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and more advanced stages than non-Hispanic whites. The study was recently published in Cancer Medicine.1 “While we know the risk of...
Rituximab Adds Benefit to Chemotherapy in Adult B-Cell Precursor ALL
The addition of rituximab (Rituxan) to the pediatric-inspired chemotherapy protocol for B-cell precursor acute lymphoblastic leukemia (ALL) significantly improved event-free survival in a large European study presented at the 2015 ASH Annual Meeting.1 The GRAALL-R 2005 phase III study is the first...
Study Suggests Luminal A Breast Cancer Patients May Not Need Chemotherapy
The ability to classify breast cancer according to biologic subtype has enabled researchers to dig deeper and determine which therapies benefit specific subgroups. Encouraging evidence from an analysis of a Danish trial presented at the 2015 San Antonio Breast Cancer Symposium suggests that...
Could CAR-T Therapy Be Moving Into Lymphoma?
The use of T cells that are genetically engineered to express chimeric antigen receptor (CAR-T) has made headway as an approach to hematologic malignancies, with the best results achieved in leukemia. At the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, a preliminary...
Expert Point of View: Paul Bunn, Jr, MD
Although the results for E1505 were negative, “overall survival and disease-free survival are not the only things we can learn from this trial,” said Paul Bunn, Jr, MD, Distinguished Professor in the Division of Medical Oncology at the University of Colorado, Denver, who formally discussed the...
Bevacizumab Plus Chemotherapy Fails to Prolong Survival in Early-Stage Lung Cancer
Overall survival in patients with surgically resected early-stage non–small cell lung cancer (NSCLC) did not improve with the addition of bevacizumab (Avastin) to chemotherapy, according to the findings of a study researchers have called a “top abstract” from the 16th World Conference on Lung...
The 340B Drug Pricing Program: Background, Concerns, and Solutions
The 340B Drug Pricing Program was created by Congress through the Veterans Health Care Act of 1992 to allow some health-care entities—including safety-net providers with large shares of uninsured and low-income patients and other “covered entities”—to obtain drugs at discounted prices.1,2 Congress...
Multiple Myeloma in 2015: A Year for the Record Books
Few malignancies have received as much attention, in the way of newly approved drugs, as multiple myeloma did in 2015. In November alone, 3 new agents were approved, bringing the total to 4 for the year as part of a record 7 approvals and to 16 regulatory approvals over the past 12 years. Speakers...
Study Finds Alectinib Highly Active in ALK-Positive, Crizotinib-Resistant NSCLC
In a North American phase II trial reported in The Lancet Oncology, Shaw et al found that alectinib (Alecensa), which is active against acquired crizotinib (Xalkori) resistance mutations and exhibits high central nervous system (CNS) penetration, was associated with considerable activity in...
